atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe
Portfolio Pulse from
Analysts at Jefferies suggest that Beckley Psytech's intranasal 5-MeO-DMT candidate BPL-003 could offer superior value compared to GH Research's drug for treatment-resistant depression. This is seen as a positive development for atai Life Sciences, an investor in Beckley.
February 06, 2025 | 7:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analysts believe Beckley Psytech's BPL-003 could offer superior value, which is positive for atai Life Sciences, an investor in Beckley.
The positive analyst outlook on Beckley Psytech's BPL-003, in which atai Life Sciences is an investor, suggests potential upside for ATAI's stock. The superior value proposition of BPL-003 compared to a competitor's drug could enhance ATAI's investment value.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80